

## Product Information

### Anti-Tumor Necrosis Factor Soluble Receptor II produced in goat, IgG fraction of antiserum

Catalog Number **T2315**

Synonym: Anti-TNF sRII

#### Product Description

Anti-Tumor Necrosis Factor Soluble Receptor II is produced in goat using a recombinant human TNF soluble receptor II, expressed in *E. coli*, as immunogen. This protein represents the non-glycosylated, N-terminal methionyl form of the naturally occurring human soluble type II receptor for TNF, minus 53 amino acids from the proline-rich region just exterior to the transmembrane domain. The antibody is purified using protein G affinity chromatography.

Anti-Tumor Necrosis Factor Soluble Receptor II may be used to detect human TNF sRII by immunoblotting and ELISA. By ELISA, the antibody shows no cross-reactivity with recombinant human TNF sRI.

TNF RII (p75, CD120b) is a 75 kDa transmembrane glycoprotein originally isolated from a human lung fibroblast library.<sup>1</sup> Among the multitude of cells known to express TNF RII are monocytes,<sup>2</sup> endothelial cells,<sup>3</sup> Langerhans cells,<sup>4</sup> and macrophages.<sup>5</sup>

Mouse to human amino acid sequence identity in the TNF RII cytoplasmic domain is 73 %, while amino acid sequence identity in the extracellular region falls to 58%.<sup>6</sup> This drop in extracellular identity is reflected in the observation that human TNF- $\alpha$  is not active in the mouse system.<sup>6</sup> TNF RII to TNF RI, amino acid sequence identity is only about 20% in the extracellular region and 5% in the cytoplasmic domain.<sup>6</sup>

TNF RII consists of a 240 amino acid residue extracellular region, a 27 amino acid residue transmembrane segment and a 173 amino acid residue cytoplasmic domain.<sup>7,8</sup>

TNF R1 and TNF R2 are members of a family of structurally related membrane receptors that includes lymphotoxin receptor, Fas, WSL-1, DR4, CD40, CD30, CD27, 4-1BB, OX40, and p75 nerve growth factor receptor.<sup>9</sup> Members of the TNFR family can interact through their cytoplasmic domains with a range of intracellular signaling proteins, most of which fall into two distinct groups. The first is the death domain-containing proteins, including TRADD, FADD/MORT1, and RIP, which associate directly with receptors also containing death domains, such as TNF R1 and Fas.<sup>10-12</sup> The second is the TRAF proteins. TRAF1 and TRAF2 were originally identified by their association with the cytoplasmic domain of TNF R2.<sup>13</sup> TRAF proteins appear to function as adaptor proteins. TRAF2 directly binds at least eight intracellular molecules, including TRAF1, c-IAP1, c-IAP2, I-TRAF/TANK, A20, TRIP, RIP, and NIK.<sup>13-20</sup> The best characterized TRAF-mediated signal transduction pathway is the activation of NF- $\kappa$ B transcription factors. TRAF2 mediates NF- $\kappa$ B activation via the recruitment of the serine/threonine kinase NIK,<sup>20</sup> which can in turn activate CHUK, an IB-specific kinase that triggers IB degradation.<sup>21,22</sup> In addition to recruiting mediators of NF- $\kappa$ B activation, TRAF2 can bind at least three other molecules, I-TRAF/TANK, A20, and TRIP, that inhibit its ability to activate NF- $\kappa$ B.<sup>16-18</sup>

#### Reagent

Supplied lyophilized from a 0.2  $\mu$ m filtered solution in phosphate buffered saline and 5% trehalose.

#### Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.

### Preparation Instructions

To one vial of lyophilized powder, add 1 mL of sterile PBS to produce a 1 mg/mL stock solution of antibody.

### Storage/Stability

Prior to reconstitution, store at  $-20^{\circ}\text{C}$ . Reconstituted product may be stored at  $2-8^{\circ}\text{C}$  for up to one month. For prolonged storage, freeze in working aliquots at  $-20^{\circ}\text{C}$ . Avoid repeated freezing and thawing.

### Product Profile

Immunoblotting: a working concentration of 1-2  $\mu\text{g/mL}$  is determined using recombinant human TNF sRII at 5 ng/lane under non-reducing conditions.

Indirect ELISA, a working concentration of 0.5 -1  $\mu\text{g/mL}$  is determined to detect recombinant human TNF sRII to a limit of 78 pg/well.

**Note:** In order to obtain the best results in various techniques and preparations, we recommend determining optimal working dilutions by titration.

Endotoxin level is  $< 0.1$  EU per 1  $\mu\text{g}$  antibody as determined by the LAL method.

### References

1. Smith, C.A., et al., *Science*, **248**, 1019 (1990).
2. Lien, E., et al., *Eur. J. Immunol.*, **25**, 2714 (1995).
3. Bradley, J.R., et al., *Am. J. Pathol.*, **146**, 27 (1995).
4. Wang, B., et al., *Immunology*, **88**, 284 (1996).
5. de Rochemonteix, B.G., et al., *Am. J. Respir. Cell Mol. Biol.*, **14**, 279 (1996).
6. Lewis, M., et al., *Proc. Natl. Acad. Sci. USA*, **88**, 2830 (1991).
7. Gruss, H-J., and Dower, S.K., *Blood*, **85**, 3378 (1995).
8. Smith, C.A., et al., *Science*, **248**, 1019 (1990).
9. Smith, C. A., et al., *Cell*, **76**, 959 (1994).
10. Hsu, H., et al., *Cell*, **81**, 495 (1995).
11. Chinnaiyan, A.M., et al., *Cell*, **81**, 505 (1995).
12. Boldin, M.P., et al., *J. Biol. Chem.*, **270**, 7795 (1995).
13. Rothe, M., et al. *Cell*, **78**, 681 (1994).
14. Cheng, G., and Baltimore, D., *Genes Dev.*, **10**, 963 (1996).
15. Rothe, M., et al., *Cell*, **83**, 1243 (1995).
16. Roth, M., et al., *Proc. Natl. Acad. Sci. USA*, **93**, 8241 (1996).
17. Song, H.Y., et al. , *Proc. Natl. Acad. Sic. USA*, **93**, 6721 (1996).
18. Lee, S.Y., et al. , *J. Exp. MAD.* , **185**, 1275 (1997).
19. Hsu, H., et al., *Immunity*, **4**, 387 (1996).
20. Malinin, N.L., et al., *Nature*, **385**, 540 (1997).
21. Régnier, C.H., et al., *Cell*, **90**, 373 (1997).
22. DiDonato, J.A., et al., *Nature*, **388**, 548 (1997).

KAA,PHC 03/08-1